Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Chippenham hairdresser and teacher lose 22 stone in weight loss pact
A hairdresser and his teacher from Swindon entered into a weight loss pact together and have since lost 22 stone. Joshua Hilton, 30, from Chippenham, managed to lose nine stone in 12 months with the ...
Gemma Collins flaunts new look and ditches shape-wear after weight loss journey
Gemma Collins took to Instagram to share a snap of herself looking glam and told her followers that she no longer has to wear ...
How Much Weight Can I Safely Lose in Just a Week?
Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...
Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...
STAT3h
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Is Novo Nordisk (NVO) the Best Falling Stock to Invest in Right Now?
We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...